ABERA — Abera Bioscience AB Cashflow Statement
0.000.00%
- SEK122.82m
- SEK116.73m
Annual cashflow statement for Abera Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -3.64 | -9.16 | -19.4 | -16.8 | -1.12 |
Depreciation | |||||
Changes in Working Capital | 0.893 | -0.516 | -0.299 | -0.91 | 0.861 |
Change in Accounts Receivable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -2.75 | -9.68 | -19.7 | -17.7 | -0.198 |
Capital Expenditures | — | — | — | — | -1.13 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -0.025 | — |
Acquisition of Business | |||||
Cash from Investing Activities | — | — | — | -0.025 | -1.13 |
Financing Cash Flow Items | — | -2.37 | -0.892 | -0.009 | -0.1 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1 | 20.7 | 23.2 | 5.6 | 4.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.75 | 11 | 3.48 | -12.1 | 2.77 |